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Abstract
In our ongoing modification study of neo-tanshinlactone (1), we discovered 2-(furan-2-
yl)naphthalen-1-ol (FNO) derivatives 3 and 4 as a new class of anti-tumor agents. To explore
structure-activity relationships (SAR) of this scaffold, 18 new analogs, 6–12 and 14–24, were
designed and synthesized. The C11-esters 7 and 12 displayed broad anti-tumor activity (ED50 1.1–
4.3 µg/mL against seven cancer cell lines), while C11-hydroxymethyl 14 showed unique
selectivity against the SKBR-3 breast cancer cell line (ED50 0.73 µg/mL). Compounds 15 and 22
displayed potent and selective anti-breast tumor activity (ED50 1.7 and 0.85 µg/mL, respectively,
against MDA-MB-231). The SAR results demonstrated that the substitutions from the ring-opened
lactone ring C of 1 are critical to the anti-tumor potency as well as the apparent tumor-tissue type
selectivity. Treatment with 3 in Brca1f11/f11p53f5&6/f5&6Crec mice models significantly inhibited
the proliferation of mammary epithelial cells and branching of mammary glands.
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Neo-tanshinlactone (1), a natural product from Salvia miltiorrhiza, and its analog, 4-ethyl
neo-tanshinlactone (2), are potent and selective anti-breast cancer agents (Figure 1).1–3 In
our prior studies, they exhibited high tumor tissue-type as well as breast cancer cell line
selectivity. The selective anti-breast tumor activity of 2 in mice models is consistent with the
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results in vitro.3 In our continuing study, we explored how the individual rings A–D in the
molecule influence the in vitro anti-breast tumor activity. The results led to the discovery of
a novel class of anti-breast cancer agents, 2-(furan-2-yl)naphthalen-1-ol (FNO) analogs
(e.g., 3 and 4) by opening ring-C.4 Our previous studies also explored the preliminary SAR
and proved that the C8 and C11 substituents can greatly affect both potency and selectivity.
FNO analog 3 showed significant potency (ED50 0.3 µg/mL) and selectivity against the
ZR-7-51 (ER+, HER2+) cell line compared with other cancer cell lines tested, while 4
exhibited activity against all cancer cell lines tested.4 We wanted to use these promising
results to design novel analogs with better pharmaceutical profiles and develop them as
clinical trials candidates.
The initial studies showed that Et, H, and Me groups are preferred at the C4, C14, and C15
positions, respectively, of the FNO skeleton, and we retained this substitution pattern in our
current study.4 However, we expanded the identities of the groups at the C8 and C11
positions (3 and 4 contain hydroxyl/carboxylic acid and methyl ether/methyl ester,
respectively). Some of the different combinations at these positions included ether/
carboxylic acid, ether/ester, ether/amide, and ether/substituted methyl. We incorporated
groups with different sizes and electrostatic effects to establish SAR and develop new lead
compounds.
As shown in Scheme 1, carboxylic acids 5 and 6, synthesized by the method reported before,
4 were converted to esters 7, 8, and 12, respectively, with thionyl chloride and the
appropriate alcohols at room temperature.5 In addition, treatment of 5 with Lawesson’s
reagent led to methylthioate 9,3 with methanamine to amide 10, and with
hydroxybenzotriazole (HOBt) to benzotriazole ester 11. Meanwhile, known diol 13 was
treated with iodomethane or iodoethane in the presence of Cs2CO3 to generate
phenoxyethers 14 and 15, respectively.5 The primary hydroxyl groups of 14 and 15 were
alkylated with iodomethane, iodoethane, or 1,1,1-trifluoro-2-iodoethane in the presence of
sodium hydride to obtain 17, 18, 20, and 23. Acetates 16, 21, and 24 were synthesized by
acetylation of 13–15 with Ac2O in pyridine. Benzylic bromination of 14 with
triphenylphosphine, bromine, and imidazole afforded bromomethyl 19. Ester 22 was
obtained by reaction of 14 with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI), 4-
dimethylaminopyridine (DMAP), and 3-(diethylamino)propanoic acid hydrochloride.
All newly synthesized analogs 6–12 and 14–246 were tested for cytotoxic activity against a
focused panel of human tumor cell lines according to previously published methods (Table
1).3 Cell lines included A549 (non small cell lung cancer), DU145 (prostate cancer cell line),
KB (nasopharyngeal carcinoma) and KB-VIN (MDR KB subline selected using vincristine),
MDA-MB-231 (estrogen receptor negative basal-like breast cancer), SK-BR-3 (estrogen
receptor negative, HER2 over-expressing luminal-like breast cancer), and ZR-75-1 (estrogen
receptor positive breast cancer, HER2 over-expressing luminal-like breast cancer).
Among analogs (6–12) with ether (OR1) and ester or similar (R2) groups at C8 and C11,
respectively, compound 12 (ethyl ether, methyl ester) showed comparable activity to 4
(methyl ether, methyl ester). The potencies were affected greatly by the R2 functional group,
with the following rank order: COOMe (12) ~ COOEt (7) > CSOMe (9) ≫ COOPr (8),
CONHMe (10), COOH (6). Free carboxylic acid, larger ester, thioester, and amide groups
(6, 8, 9, 10) dramatically reduced or eliminated potency. The results also suggested that the
combination of ether and carboxylic ester at C8 and C11, respectively, may lead to broad
inhibition of cancer cell lines from different tissues (4, 7, 9, and 12). Small ester groups,
including COOMe (4, 12) and COOEt (7), were preferred at C11.
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Among analogs (14–24) with ether (OR3) and substituted methyl (CH2R4) groups at C8 and
C11, respectively, compound 14 with a C11 hydroxymethyl group (R4 = OH) displayed
significant potency and unique selectivity, being more than nine-fold more active against the
SKBR-3 breast cancer cell line (ED50 0.73 µg/mL) compared with other cancer cell lines
tested (ED50 6.6 – >10 µg/mL). Interestingly, compound 15, in which the C8 methyl ether
(OR3 = OMe) of 14 is replaced by an ethyl ether (OR3 = OEt), showed high potency and
selectivity against ZR-75-1 and MDA-MB-231 (ED50 1.4 and 1.7 µg/mL, respectively).
These results indicate that the size of the R3 group could change the apparent cell line
selectivity. Compounds 15 and 22 (R4 = OCOCH2CH2NEt2; ED50 1.7 µg/mL, ZR-75-1;
0.85 µg/mL, MDA-MB-231) displayed comparable activity against all cell lines tested.
Changing the R4 group in the C11 substituent to other groups (e.g., acetate, bromide,
methoxy) generally led to lower potency. Although diacetate 16 (R4 = OR3 = OAc) was
completely inactive, monoacetates 21 and 24 (R4 = OAc, R2 = Me and Et, respectively)
were active against ZR-75-1 (21 and 24) and MDA-MB-231 (24). The bromomethyl
compound 19 (R4 = Br) was also selective against ZR-75-1, and 23 (R4 = OMe) showed
moderate activity against MDA-MB-231. These results suggested that the identity of the R4
group might affect selectivity against ZR-75-1. Interestingly, 23 and 24 showed some
growth inhibition against the P-glycoprotein over-expressing KB-VIN cell line, but no
inhibition against the parent KB cell line. Further work will be needed to determine whether
the apparent MDR-selectivity of 23 and 24 is significant.
Subsequently, we evaluated the anti-proliferation activity of 3. BRCA1 is the first cloned
familial breast cancer susceptibility gene that is expressed in all cells.7,8 BRCA1 mutations
significantly increase breast and ovarian cancer risk in female carriers. Male BRCA1 carriers
also have increased breast cancer risk, but the risk factor is lower than that of BRCA2
carriers.8 The BRCA1 protein plays a critical role in DNA damage repair, cell cycle
checkpoint control, and transcriptional regulation.9,10 Brca1f11/f11p53f5&6/f5&6Crec mice
show extensive mammary epithelial proliferation that can be effectively inhibited by the
progesterone antagonist mifepristone (RU 486).11 Thus, this mouse model can provide
critical information on in vivo activity of novel experimental anti-breast tumor agents.
To assess the effects of 3 on mammary epithelial proliferation in vivo, we treated
Brca1f11/f11p53f5&6/f5&6Crec mice and wild-type mice with 3.12–14 As previously reported,
mammary glands from control vehicle-treated Brca1f11/f11p53f5&6/f5&6Crec mice showed
remarkable accumulation of side branches and extensive alveolar formation compared with
similarly treated wild-type mice at three months of age (Figure 2A, a & c). Compared with
vehicle-treated control, mammary gland branching points in Brca1f11/f11p53f5&6/f5&6Crec
and wild-type mice were significantly reduced, with a 70 ± % reduction in the former and a
29 ± % reduction in the latter (Figure 2A, b & c; Figure 2B).
To address the inhibitory effects of 3 on mammary epithelial cell proliferation,
bromodeoxyuridine (BrdU) was used for labeling the S-phase. Drinking water containing
BrdU (1 mg/mL) was supplied to mice during the last three days of treatment. BrdU-positive
mammary epithelial cells were quantified and found to be about 3.5 fold higher in the
vehicle-treated Brca1/p53-deficient mice than wild-type mice (Figure 3A, a & c; Figure 3B),
indicating that the proliferation of mammary gland in Brca1/p53-deficient mice is 3.5 fold
higher than wild-type. In 3-treated wild-type mice, BrdU positive mammary epithelial cells
were undetectable, while BrdU-positive cells were found occasionally in the extracellular
matrix of the mammary gland (Figure 3A, b). These findings indicated that the inhibitory
effects of 3 are likely specific to the mammary epithelial cells. Treatment of Brca1/p53-
deficient mice with 3 dramatically reduced BrdU-positive mammary epithelial cells (83%)
(Figure 3A, d; Figure 3B). This result implied that 3 inhibited the onset of the cell-cycle S-
phase in both wild-type and Brca1/p53-deficient mammary epithelial cells.
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In summary, we established the SAR of FNO analogs and developed lead compounds with
high potency and selectivity. The results indicated that the C8 and C11 substituents, which
are analogous to the opened ring-C, play a critical role in both potency and apparent tumor-
tissue selectivity. Compounds 7 and 12 displayed broad activity spectrum against all cancer
cell lines tested, while 15 and 22 showed more than four-fold greater potency against
ZR-751 and MDA-MB-231 (ED50 1.7 and 0.85 µg/mL, respectively, against ZR-751), and
14 showed more than nine-fold greater potency against SKBR-3 (ED50 0.73 µg/mL). Based
on this study, SAR results are as follows. (1) The combination of ether at C8 and ester at
C11 may lead to broad inhibition of cancer cell lines from different tissues, and the
combination of ether at C8 and carboxylic acid at C11 is not favored. (2) Small ester groups
at C11 are preferred. (3) An acetoxymethyl or bromomethyl group at C11 might induce
selectivity against ZR-75-1.
Proliferation of mammary epithelial cells is regulated by ovarian hormones.15 Several
studies have indicated that BRCA1 suppresses the hyperactivation of estrogen and
progesterone receptors.16 Mutation in BRCA1 leads to expansion of the mammary epithelial
cells.17 The robust expansion of mammary epithelial cells in the Brca1 mouse model of
human breast cancer provides increased sensitivity and accuracy for identification and
evaluation of compounds with clinically significant anti-proliferation activity in vivo.
Although molecular targets of 3 are currently unknown, in vivo studies, including the
branching of mammary glands and the prevention of mammary epithelial cells entering S-
phase, showed that 3 has significant effects on preventing mammary epithelial cell
proliferation in both wild-type and Brca1/p53-deficient mice.
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δ 8.10 (d, 1H, J = 8.1 Hz, Ar-H), 7.84 (d, 1H, J = 8.4 Hz, Ar-H), 7.55 (d, 1H, J = 9.0 Hz, Ar-H),
7.46 (t, J 1H, = 8.4 Hz, Ar-H), 7.39 (d, 1H, J = 8.7 Hz, Ar-H), 7.35 (d, 1H, J = 0.9 Hz, OCH), 4.17
(q, 2H, J = 7.2 Hz, OCH2CH3), 3.70 (s, 3H, OCH3), 3.12 (q, 2H, J = 7.5 Hz, CH2CH3), 2.26 (d,
3H, J = 1.2 Hz, CH3), 1.39 (t, 3H, J = 7.5 Hz, CH2CH3), 1.07 (t, 3H, J = 7.2 Hz, OCH2CH3). MS
m/z 339 (M++1); Compound 8: 1H NMR (400 MHz, CDCl3, ppm): δ 8.09 (d, 1H, J = 8.0 Hz, Ar-
H), 7.83 (d, 1H, J = 8.8 Hz, Ar-H), 7.53 (d, 1H, J = 8.8 Hz, Ar-H), 7.45 (t, 1H, J = 8.8 Hz, Ar-H),
7.38 (d, 1H, J = 6.4 Hz, Ar-H), 7.34 (d, 1H, J = 1.2 Hz, OCH), 4.07 (t, 2H, J = 6.8 Hz, OCH2
CH2CH3), 3.70 (s, 3H, OCH3), 3.11 (q, 2H, J = 7.6 Hz, CH2CH3), 2.27 (d, 3H, J = 1.2 Hz, CH3),
1.45 (h, 2H, J = 7.6 Hz, OCH2 CH2CH3), 1.38 (t, 3H, J = 7.2 Hz, CH2CH3), 0.65 (t, 3H, J = 7.2
Hz, O C.H2CH2CH3). MS m/z 353 (M++1); Compound 9: 1H NMR (400 MHz, CDCl3, ppm): δ
8.08 (d, 1H, J = 8.4 Hz, Ar-H), 7.83 (d, 1H, J = 9.2 Hz, Ar-H), 7.55 (d, 1H, J = 8.8 Hz, Ar-H), 7.45
(t, 1H, J = 8.0 Hz, Ar-H), 7.38 (d, 1H, J = 6.8 Hz, Ar-H), 7.33 (d, 1H, J = 0.8 Hz, OCH), 3.96 (s,
3H, OCH3), 3.66 (s, 3H, OCH3), 3.11 (q, 2H, J = 6.8 Hz, CH2CH3), 2.28 (s, 3H, CH3), 1.39 (t, 3H,
J = 6.8 Hz, CH2CH3). MS m/z 341 (M++1); Compound 10: 1H NMR (400 MHz, CDCl3, ppm): δ
8.09 (d, 1H, J = 8.2 Hz, Ar-H), 7.88 (d, 1H, J = 8.8 Hz, Ar-H), 7.50 (m, 2H, Ar-H), 7.43 (t, 1H, J =
7.6 Hz, Ar-H), 7.32 (d, 1H, J = 1.2 Hz, OCH), 6.39 (brs, 1H, NH), 3.75 (s, 3H, OCH3), 3.10 (q, 2H,
J = 7.6 Hz, CH2CH3), 2.75 (d, 3H, J = 4.8 Hz, NCH3), 2.49 (d, 3H, J = 1.2 Hz, CH3), 1.39 (t, 3H, J
= 7.6 Hz, CH2CH3). MS m/z 324 (M++1); Compound 11: 1H NMR (400 MHz, CDCl3, ppm): δ
8.14 (d, 1H, J = 8.4 Hz, Ar-H), 8.00 (d, 1H, J = 7.6 Hz, Ar-H), 7.92 (d, 1H, J = 8.8 Hz, Ar-H), 7.70
(t, 1H, J = 7.2 Hz, Ar-H), 7.51 (m, 3H, Ar-H), 7.37 (m, 2H, Ar-H & OCH), 3.82 (s, 3H, OCH3),
3.10 (q, 2H, J = 7.6 Hz, CH2CH3), 2.35 (d, 3H, J = 1.2 Hz, CH3), 1.36 (t, 3H, J = 7.6 Hz,
CH2CH3). MS m/z 428 (M++1); Compound 12: 1H NMR (300 MHz, CDCl3, ppm): δ 8.08 (d, 1H,
J = 8.4 Hz, Ar-H), 7.83 (d, 1H, J = 8.7 Hz, Ar-H), 7.53 (d, 1H, J = 9.3 Hz, Ar-H), 7.44 (t, 1H, J =
8.1 Hz, Ar-H), 7.37 (d, 1H, J = 6.3 Hz, Ar-H), 7.32 (d, 1H, J = 0.9 Hz, OCH), 3.76 (q, 2H, J = 7.2
Hz, OCH2CH3), 3.67 (s, 3H, OCH3), 3.09 (q, 2H, J = 7.5 Hz, CH2CH3), 2.23 (d, 3H, J = 0.9 Hz,
CH3), 1.38 (t, 3H, J = 7.5 Hz, CH2CH3), 1.26 (t, 3H, J = 7.2 Hz, OCH2CH3). MS m/z 361
(M++23); Compound 14: 1H NMR (300 MHz, CDCl3, ppm): δ 8.09 (d, 1H, J = 8.4 Hz, Ar-H), 7.90
(d, 1H, J = 9.0 Hz, Ar-H), 7.55 (d, 1H, J = 8.7 Hz, Ar-H), 7.49 (dd, 1H, J = 7.2, 8.1 Hz, Ar-H),
7.40(d, 1H, J = 6.3 Hz, Ar-H), 7.37 (d, 1H, J = 1.2 Hz, OCH), 4.48 (d, 2H, J = 6.0 Hz, CH2OH),
3.70 (s, 3H, OCH3), 3.12 (q, 2H, J = 7.5 Hz, CH2CH3), 2.75 (t, 1H, J = 6.3 Hz, OH), 2.17 (d, 3H, J
= 1.2 Hz, CH3), 1.39 (t, 3H, J = 7.5 Hz, CH2CH3). HRMS Calcd for C19H21O3 (M+H+): 297.1485,
found: 297.1470; Compound 15: 1H NMR (400 MHz, CDCl3): 8.09 (d, 1H, J = 8.3 Hz, Ar-H), 7.88
(d, 1H, J = 8.8 Hz, Ar-H), 7.53 (d, 1H, J = 8.8 Hz, Ar-H), 7.48 (dd, 1H, J = 8.4 and 7.0 Hz, Ar-H),
7.40 (d, 1H, J = 7.0 Hz, Ar-H), 7.38 (br s, 1H, Ar-H), 4.47 [s, 2H, CH2OH], 3.85 (q, 2H, J = 7.1 Hz,
OCH2CH3), 3.12 (q, 2H, J = 7.5 Hz, CH2CH3), 2.17 (s, 3H, CH3), 1.39 (t, 3H, J = 7.5 Hz,
CH2CH3), 1.29 (t, 3H, J = 7.1 Hz, OCH2CH3); Compound 16: 1H NMR (400 MHz, CDCl3): 8.02
(d, 1H, J = 8.4 Hz, Ar-H), 7.73 (d, 1H, J = 8.8 Hz, Ar-H), 7.59 (d, 1H, J = 8.8 Hz, Ar-H), 7.47 (dd,
1H, J = 8.4 and 7.0 Hz, Ar-H), 7.39 (d, 1H, J = 7.0 Hz, Ar-H), 7.33 (br s, 1H, Ar-H), 5.05 [s, 2H,
CH2OAc], 3.12 (q, 2H, J = 7.5 Hz, CH2CH3), 2.10 [s, 3H, OC(O)CH3], 2.03 (s, 3H, CH3), 2.36 [s,
3H, OC(O)CH3], 2.09 [s, 3H, CH2OC(O)CH3], 2.08 (s, 3H, CH3), 1.39 (t, 3H, J = 7.5 Hz,
CH2CH3). MS m/z 389 (M++Na); Compound 17: 1H NMR (300 MHz, CDCl3, ppm): δ 8.13 (d, 1H,
J = 8.4 Hz, Ar-H), 7.85 (d, 1H, J = 9.0 Hz, Ar-H), 7.56 (d, 1H, J = 8.7 Hz, Ar-H), 7.47 (t, 1H, J =
7.2 Hz, Ar-H), 7.40(d, 1H, J = 8.4 Hz, Ar-H), 7.37 (s, 1H, OCH), 4.40 (s, 2H, CH2OH), 3.71 (s, 3H,
OCH3), 3.32 (s, 3H, OCH3), 3.11 (q, 2H, J = 7.5 Hz, CH2CH3), 2.14 (s, 3H, CH3), 1.39 (t, 3H, J =
7.5 Hz, CH2CH3). MS m/z 311 (M++1); Compound 18: 1H NMR (300 MHz, CDCl3, ppm): δ 8.13
(d, 1H, J = 8.1 Hz, Ar-H), 7.85 (d, 1H, J = 9.0 Hz, Ar-H), 7.57 (d, 1H, J = 8.7 Hz, Ar-H), 7.47 (t,
1H, J = 8.4 Hz, Ar-H), 7.40 (d, 1H, J = 8.4 Hz, Ar-H), 7.35 (d, 1H, J = 1.2 Hz, OCH), 4.44 (s, 2H,
CH2OH), 3.71 (s, 3H, OCH3), 3.48 (q, 2H, J = 7.2 Hz, OCH2CH3), 3.12 (q, 2H, J = 7.5 Hz,
CH2CH3), 2.15 (d, 3H, J = 1.2 Hz, CH3), 1.39 (t, 3H, J = 7.5 Hz, CH2CH3), 1.20 (t, 3H, J = 7.2 Hz,
OCH2CH3). MS m/z 325 (M++1); Compound 19: 1H NMR (400 MHz, CDCl3): 8.09 (d, 1H, J =
8.4 Hz, Ar-H), 7.88 (d, 1H, J = 8.8 Hz, Ar-H), 7.55 (d, 1H, J = 8.8 Hz, Ar-H), 7.49 (dd, 1H, J = 8.4
and 7.2 Hz, Ar-H), 7.44-7.35 (m, 2H, Ar-H), 4.49 [s, 2H, CH2Br], 3.70 (s, 3H, OCH3), 3.11 (q, 2H,
J = 7.4 Hz, CH2CH3), 2.17 (s, 3H, CH3), 1.39 (t, 3H, J = 7.4 Hz, CH2CH3); Compound 20: 1H
NMR (400 MHz, CDCl3): 8.12 (d, 1H, J = 8.4 Hz, Ar-H), 7.86 (d, 1H, J = 8.8 Hz, Ar-H), 7.55 (d,
1H, J = 8.8 Hz, Ar-H), 7.47 (dd, 1H, J = 8.4 and 7.2 Hz, Ar-H), 7.41-7.38 (m, 2H, Ar-H), 4.92 [s,
2H, CH2OCH2CF3], 3.71 (s, 3H, OCH3), 3.49 (t, 2H, J = 9.4 Hz, OCH2CF3), 3.11 (q, 2H, J = 7.4
Hz, CH2CH3), 2.17 (s, 3H, CH3), 1.39 (t, 3H, J = 7.4 Hz, CH2CH3). MS m/z 402 (M++Na);
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Compound 21: 1H NMR (400 MHz, CDCl3): 8.11 (d, 1H, J = 8.4 Hz, Ar-H), 7.86 (d, 1H, J = 8.8
Hz, Ar-H), 7.54 (d, 1H, J = 8.8 Hz, Ar-H), 7.46 (dd, 1H, J = 8.4 and 7.2 Hz, Ar-H), 7.40-7.36 (m,
2H, Ar-H), 5.10 [s, 2H, CH2OC(O)-], 3.70 (s, 3H, OCH3), 3.11 (q, 2H, J = 7.4 Hz, CH2CH3), 2.11
[s, 3H, C(O)CH3)], 2.04 (s, 3H, CH3) 1.39 (t, 3H, J = 7.4 Hz, CH2CH3). MS m/z 339 (M+-1);
Compound 22: 1H NMR (400 MHz, CDCl3): 8.10 (d, 1H, J = 8.4 Hz, Ar-H), 7.84 (d, 1H, J = 8.8
Hz, Ar-H), 7.54 (d, 1H, J = 8.8 Hz, Ar-H), 7.46 (dd, 1H, J = 8.4 and 7.2 Hz, Ar-H), 7.40-7.36 (m,
2H, Ar-H), 5.11 [s, 2H, CH2OC(O)-], 3.70 (s, 3H, OCH3), 3.10 (q, 2H, J = 7.5 Hz, CH2CH3), 2.74
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Structures of neo-tanshinlactone (1), 4-ethyl neo-tanshinlactone (2), and FNO analogs 3 and
4
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Treatment with 3 leads to decreased mammary ductal branching. Mammary gland whole
mounts were prepared from wild-type and Brca1f11/f11p53f5&6/f5&6Crec mice following
treatment with 0.1 mg of 3 daily for 11 days. (A) Mammary gland whole mounts of vehicle-
(a & c) and 3-treated (b & d) 3-month-old mice. (B) Number of branching points in wild-
type (wt) and Brca1f11/f11p53f5&6/f5&6Crec mammary glands. The data represent average of
branch points in five randomly selected areas ± SD. (* P≤ 0.002; ** P≤ 0.0002)
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Treatment with 3 leads to decreased mammary epithelial proliferation. BrdU-containing
drinking water was provided during the last three days of 3 treatment. (A) Cells uptaking
BrdU, indicative of DNA synthesis, were detected by immunostaining. Arrows indicate
BrdU-positive cells. (B) Quantification of BrdU-positive cells in 15 mammary ducts.
Average number of BrdU-positive cells in vehicle- and 3-treated wild-type (wt) and
Brca1f11/f11p53f5&6/f5&6Crec mice. Arrows indicate alveoli. Histogram shows the average
number of BrdU labeled cells per duct ± SD (*P≤ 0.002; **P≤ 0.0001). At least 15
mammary ducts/animal were evaluated (a minimum of three mice per genotype). Mammary
glands from vector (a & c) or 3 (b & d) treated mice were removed and fixed with
paraformaldehyde. Paraffin sections were labeled with antibody to cyclin D1. At least 15
mammary ducts/animal were evaluated.
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Reactions and conditions: (a) NaOH, 18-crown-6, R1I, CH3CN, 90 °C; (b) SOCl2, R2OH, rt;
(c) (i) SOCl2, MeOH, rt; (ii) Lawesson’s reagent, toluene, reflux, 5h; (d) HOBt, EDCI,
CH2Cl2, (H2NMe for 10); (e) MeI or EtI, Cs2CO3, acetone, rt; (f) Ac2O, Py, DMAP, 90 °C;
(g) MeI or EtI, NaH, THF, rt, (CF3CH2I, DMF, 0 °C for 20); (h) PPh3, Br2, imidazole, 0 °C
to rt; (i) EDCI, DMAP, 3-(diethylamino)-propanoic acid hydrochloride, CH2Cl2, rt.
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